Stay updated on Durvalumab in Resectable Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab in Resectable Lung Cancer Clinical Trial page.

Latest updates to the Durvalumab in Resectable Lung Cancer Clinical Trial page
- Check6 days agoChange DetectedA new revision entry v3.5.4 was added to the record history, replacing the previous v3.5.3 entry and indicating a minor update in the page's version history.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedNew content sections Adverse Events and Outcome Measures (Results) were added to the study record history. The history also shows a Returned date of 2026-04-24 and a new Revision (v3.5.3) with QC status Has Not Concluded, replacing the prior Revision v3.5.2.SummaryDifference0.5%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedRevision history shows the addition of v3.5.2 and removal of v3.5.0.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded revision v3.5.0 and removed revision v3.4.3 from the record history.SummaryDifference0.1%

- Check70 days agoChange DetectedA new Revision: v3.4.3 was added and Revision: v3.4.2 was removed from the history.SummaryDifference0.1%

- Check99 days agoChange DetectedAdded Revision: v3.4.2. The funding lapse notice and the previous Revision: v3.4.1 were removed.SummaryDifference0.4%

Stay in the know with updates to Durvalumab in Resectable Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab in Resectable Lung Cancer Clinical Trial page.